CD8A and cancer: ICIs, particularly anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies, which activate CD8-positive T cells and induce cancer cell mortality, have revolutionized the treatment of advanced cancers.